US20070203185A1 - Therapeutical Composition Containing Dentritic Cells And Use Thereof - Google Patents

Therapeutical Composition Containing Dentritic Cells And Use Thereof Download PDF

Info

Publication number
US20070203185A1
US20070203185A1 US10/559,375 US55937504A US2007203185A1 US 20070203185 A1 US20070203185 A1 US 20070203185A1 US 55937504 A US55937504 A US 55937504A US 2007203185 A1 US2007203185 A1 US 2007203185A1
Authority
US
United States
Prior art keywords
tlr
agonist
lymphocytes
malp
ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/559,375
Other languages
English (en)
Inventor
Peter Muhlradt
Armin Braun
Norbert Krug
Henning Weigt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Original Assignee
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum fuer Infektionsforschung HZI GmbH filed Critical Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Assigned to HELMHOLTZ ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH reassignment HELMHOLTZ ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WEIGT, HENNING, BRAUN, ARMIN, KRUG, NORBERT, MUHLRADT, PETER F.
Publication of US20070203185A1 publication Critical patent/US20070203185A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464839—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Definitions

  • This invention relates to a therapeutical composition, a method of its preparation, and corresponding methods of use, especially as a vaccine within a method of treatment for tumor associated disorders, infectious disorders and transplantation associated disorders or treatment of allergic disorders.
  • the invention is related to the field of immunotherapy where in general pretreated dendritic cells are used as vaccines to stimulate or modulate an individual immune response.
  • DC Dendritic cells
  • DC are also described to induce under the appropriate conditions an unpolarized Th-0 response, or else they may anergize T-cells which results in tolerance.
  • the mechanisms involved in this plasticity are affinity and duration of MHC II-TCR interaction, the expression pattern of costimulatory molecules, and the availability of cytokines (Kalinski P, Hilkens C M, Wierenga E A, Kapsenberg M L. Immunol Today 1999; 20(12):561-7).
  • antigen-pulsed DC i.e. DC loaded with antigens
  • the purpose is to immunize patients in need thereof against tumors (see e.g. Brossart et al. Exp. Hematol. 291247 (2001)), infectious agents or other pathogens (see review of Moll and Berberich, J. Med. Microbiol. 291323 (2001)).
  • Great efforts are made with respect to the treatment of tumors that have become resistant to conventional therapeutical means. Especially in tumor therapy it is highly desirable to induce a sufficient antigen-specific Th-1 response.
  • Dendritic cells can be prepared using different techniques. For human DC the preparation derived from blood monocytes is currently the most efficient. This method generates sufficient numbers of autologous DC. Such DC have been in vitro treated with several stimulatory compounds to mature and induce proliferation of lymphocytes. E.g. DC that were treated with MALP-2 or LPS induced a marked proliferation of autologous lymphocytes, but no significant polarization of lymphocytes into T-helper (Th-1) cells (Weigt, H., Mühlradt, P. F., Emmendorffer, A., Krug, N. Braun, A., Immunobiol. 2003 May 1; 207(3): 161-8).
  • Th-1 T-helper
  • lipopeptides and in particular MALP-2 are useful for treating lung infections and lung tumors, e.g. by intratracheal instillation thereof (WO 02/28887).
  • One object of this invention is to find a method to modulate an existing Th-2 response towards Th1 response or to provoke or enhance a Th-1 response and to influence the lymphocyte modulating potential of DC in the aforementioned direction since this is deemed to be an approach e.g. towards causative treatment of allergic disorders.
  • Another object of the invention is to provide a diagnostic tool to test the immune status of a patient.
  • the magnitude of an immuneresponse after in vitro Th-1 stimulation of the cells of a patient can be quantified and compared to standard values.
  • the inventors now discovered that in vivo or in vitro treatment of DC or tissue containing DC with a toll-like receptor 2 and/or toll-like receptor 6 agonist in combination with an IFN ⁇ receptor agonist stimulate DC to induce a Th-1 typical response in lymphocytes.
  • the DC cells used in connection with this invention can be taken from any suitable source.
  • the source of DC includes progenitor derived DC, e.g., monocyte derived DC and stem cell derived DC, or DC from in viva sources, e.g., blood derived DC. Techniques to obtain DC from human blood monocytes are described e.g. in T. G. Berger et al., J. Immunol. Methods 268: 131-140 (2002).
  • the DC used should preferably be derived from autologous monocytes of a person or animal to be treated with the therapeutical composition according to the invention.
  • the therapeutical composition for the preparation of the therapeutical composition according to one embodiment of the present invention there is added at least one IFN ⁇ receptor agonist and at least one TLR 2 and/or TLR 6 agonist to a culture or solution of dendritic cells from any source whereupon this mixture is further used for the preparation of a therapeutical composition or as a therapeutical composition as such.
  • the DC and receptor agonists as described below are cocultivated for at least 12 hours, preferably 48 hours. For the details reference is made to the examples.
  • the culture of the DC may further contain growth factors, cytokines, antigens, cells and/or substances, especially salts, nutrients, or other auxiliary agents and/or drugs.
  • the DC are washed after the first cultivation period and used for the further preparation of a therapeutical composition or as a therapeutical composition as such, preferably resuspended in saline, or any other physiological solution.
  • the DC are then, after the first treatment with both agonists, i.e. after the first cultivation period, loaded with appropriate antigens according to established methods (e.g. Feuerstein et al. J. Immunol. Methods 245: 15-29 (2000)).
  • lymphocytes which are preferably autologous or allogenic lymphocytes acquired from the peripheral blood of donors, are added from the beginning or after the first cultivation period, whereafter the DC, the lymphocytes and optionally further ingredients are cocultivated for a time period up to several days, preferably for at least 12 or 48 hours, more preferred at least 3 days, and wherein the resulting culture is used for the further preparation of a therapeutical composition or as a therapeutical composition as such.
  • lymphocytes can be separated from the culture, optionally washed and used for the further preparation of a therapeutical composition or as a therapeutical composition as such, preferably resuspended in, saline, or any physiological solution.
  • a pharmaceutical composition comprising effective amounts of at least one IFN ⁇ receptor agonist and at least one TLR 2 and/or TLR 6 agonist and a pharmaceutically acceptable carrier and/or diluent.
  • the pharmaceutical composition according to the present invention allows for modulation of DC in vivo by simply administering of at least one IFN ⁇ receptor agonist and at least one TLR 2 and/or TLR 6 agonist and a pharmaceutically acceptable carrier and/or diluent to a person in need thereof.
  • the pharmaceutical composition is adapted for inhalative administration, e.g. intratracheal instillation.
  • the IFN ⁇ receptor agonist is human interferon gamma or a variant thereof, since most applications will be for human beings. In general the appropriate species-specific IFN ⁇ or variant should be used. Suitable interferon gamma receptor agonists are e.g. disclosed in Ioannovich et al. Intensive Care Med 1996 October; 22 Suppl 4:S468-73. Musial et al. Allergy. 1995 June; 50(6):520-3. Reumann. Pediatr Infect Dis J. 2001 October; 20(10):995-6. Review. Aulitzky et al. Immunobiology. 1990 June; 180(4-5):385-94.
  • the term IFN ⁇ receptor agonist encompasses natural as well as synthetic molecules, including parts and derivates thereof as far as a sufficient activity to bind to the IFN ⁇ receptor is retained.
  • the toll-like receptor 2 and/or 6 agonist is preferably an agonist capable to signal via both toll-like receptors 2 and 6, like e.g. MALP-2 (see below); the agonist can also be a toll-like 2 or a toll-like 6 receptor agonist as far as a sufficient stimulation of DC can be achieved.
  • the TLR 2 / 6 agonist is a bisacyloxypropyl-S-cystein derivative, or a lipopeptide derived from Mycoplasma fermentans or a corresponding synthetic lipopeptide capable to stimulate macrophage in vitro or in vivo, preferably Marophage Activating Lipopeptide 2 kDa (MALP-2) or biologically active derivates thereof, shown to be less pyrogenic then LPS (Deiters et al. Infect Immun. 2003, August; 71(8):4456-62).
  • Suitable MALP variants are for example described in Morr M., Takeuchi O., Akira S., Simon M. M., Mühlradt P. F., Eur. J. Immunol.
  • the toll-like receptor agonist molecules can be chemically modified, for example pegylated as disclosed for different proteins in EP 0 510 356 B1 and references cited therein.
  • S-[2,3-bis(palmitoyloxy)-(2S)-propyl]-L-cysteinyl-carboxy-polyethylenglykol or S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-L-cysteinyl-carboxy-polyethylenglykol are preferred.
  • compositions according to this invention are useful as vaccines, for cell therapy and for the treatment of allergic disorders, malignancies, infectious disorders including viral, bacterial, fungal and parasite infections, autoimmune disorders and host-versus-graft or graft-versus-host reactions in transplantation.
  • they contain DC and/or lymphocytes cocultivated with said DC, where the DC have acquired the property to drive a T helper cell type I response.
  • the pharmaceutical composition contains effective amounts of at least one IFN ⁇ receptor agonist and at least one TLR 2 and/or 6 agonist.
  • This invention further teaches the use of DC in combination with a least one IFN ⁇ receptor agonist and at least one TLR 2 and/or 6 agonist and the appropriate antigens or antigen delivering or encoding vectors according to the respective application for the manufacture of a medicament for the treatment of allergic disorders, in particular of allergic airway disease, like asthma, e.g. in human or horses, cancer, e.g. melanoma, renal and prostate carcinoma or pancreas carcinoma, of viral infections, e.g. by HIV, Herpes and influenza, of bacterial infections, e.g. by Listeria, Salmonella, Mycobacteria, Chlamydia and Borrelia, of fungal infections, especially Candida, Aspergillus, Actinomyces.
  • autoimmune disorders e.g. Lupus erythematosus, type 1 diabetes and multiple sclerosis, and of transplantation associated diseases, especially graft-versus-host disease and host-versus-graft disease.
  • the medicament or the therapeutical composition of the invention may further contain pharmaceutically acceptable carriers or preservatives. That means, for medical use diluents, pharmaceutically acceptable carriers, auxiliary agents, drugs, and so on, can be added to the therapeutical composition obtained from said cells and/or mixtures to meet practical needs.
  • the invention encompasses the use of at least one IFN ⁇ receptor agonist in combination with at least one TLR 2 and/or TLR 6 agonist for the treatment of DC in vivo or in vitro.
  • the therapeutical composition can be applied for example intradermally, subcutaneously, intravenously, inhalatively, intranasally, intranodally or in the case of cancer by injection into or near the tumor.
  • the invention also covers the use as a diagnostic tool to monitor the immune status of persons or animals. This is achieved by cocultivating DC which have been prestimulated with at least one IFN ⁇ receptor agonist and at least one TLR 2 and/or TLR 6 agonist with autologous or allogenic lymphocytes and measuring proliferation, release of molecules, cytotoxic activity and antibody formation. These parameters can be quantified and compared to standard values. A hyper- or hyporesponse to the stimuli indicates an imbalanced immune status.
  • the invention relates to methods for treatment of a subject in need thereof with dendritic cells and/or lymphocytes prepared according to the methods of the present invention.
  • the invention provides for a method of treating a subject with at least one IFN ⁇ receptor agonist and at least one TLR 2 and/or TLR 6 agonist.
  • toxicity and therapeutical effects of the respective compounds can be determined by standard to pharmaceutical procedures in cell cultures or experimental animals, e.g. for determining the LD 50 and the ED 50 .
  • the dose ratio between toxic and therapeutical effects is the therapeutic index and can be expressed as the ratio LD 50 /ED 50 .
  • the dosage may vary due to various individual factors, like conditions of the subject, weight, age etc. of the subject, or the application form chosen for the administration of the therapeutical composition.
  • FIG. 1 Production of the cytokines IFN-g and IL-4 in the coculture of autologous lymphocytes with allergen-pulsed (DerP1) versus unpulsed (PBS) DC. DerP1 sensitive and healthy donors are opposed. The bracket indicates a significant difference (p ⁇ 0.05) between the compared groups.
  • FIG. 2 Flow cytometric analysis of DC harvested after 7 days of culture. The fluorescence profile of isotype-matched control, allergen-pulsed DC or allergen-pulsed and MALP-2+IFN-g treated DC of one representative experiment is shown for each cell surface molecule.
  • FIG. 3 Production of the cytokines IL-10 (a), IL12p70 (b) and TNF- ⁇ (c) after treatment of immature DC with PBS, DerP1, DerP1+MALP-2, DerP1+IFN-g or DerP1+MALP-2+IFN-g.
  • the bracket indicates a significant difference (p ⁇ 0.05) between the compared groups.
  • FIG. 4 Proliferative response measured by 3H-Thymidine incorporation after coculture of DC pretreated with PBS, DerP1, DerP1+MALP-2, DerP1+IFN-g or DerP1+MALP-2+IFN-g and autologous lymphocytes.
  • Each curve represents the mean of 6 individual experiments of titrated DC cocultured with a constant number of lymphocytes. The last point (lymphocytes) shows lymphocytes without DC.
  • FIG. 5 Ratio of IFN-g production to IL-4 production after coculture of DC pretreated with PBS, DerP1, DerP1+MALP-2, DerP1+IFN-g or DerP1+MALP-2+IFN-g and autologous lymphocytes.
  • FIG. 6 Schematic presentation of the study design according to example 2.
  • Female Balb/c mice were sensitized by i.p. injection of Ovalbumin adsorbed to Alum (controls received only Alum) on day 0, 14 and 21.
  • mice were i.t.treated with NaCl, MALP-2, IFN- ⁇ or the combination of MALP-2 and IFN- ⁇ . All groups received OVA aerosol challenge on days 28 and 29. 24 hours later head-out body plethysmography was performed to measure AHR followed by animal dissection.
  • FIG. 7 Detection of IL-4, IL-5, IL-13 and IL-12p70 in the BALF 24 hours after the last allergen challenge.
  • Groups have been sham-sensitized and -treated (NaCl/NaCl), OVA-sensitized and NaCl treated (OVA/NaCl), sensitized and MALP-2 treated (OVA/MALP-2), sensitized and IFN- ⁇ treated (OVA/IFN- ⁇ ) or sensitized and MALP-2+IFN- ⁇ treated (OVA/MALP-2+IFN- ⁇ ).
  • One asterisk gives p ⁇ 0.05, while two asterisks show p ⁇ 0.01 vs. the OVA/NaCl positive control.
  • FIG. 8 Cellular composition in the broncho-alveolar lavage fluid (BALF) 24 hours after the last allergen challenge. Groups have been treated as described in FIGS. 1 and 2 . One asterisk gives p ⁇ 0.05, while two asterisks show p ⁇ 0.01 vs. the OVA/NaCl positive control.
  • FIG. 9 Lung histology 24 h after the last allergen challenge. 5 ⁇ m thick cryostat section were stained with hematoxilin/eosin. Mice have been sham-sensitized and -treated (A), OVA-sensitized and NaCl-treated (B) or OVA-sensitized and treated with MALP-2+IFN- ⁇ (C).
  • Figure D displays a lung from the OVA-sensitized, MALP-2+IFN- ⁇ treated group 7 days after the last allergen challenge. Image acquisition was performed using a 20-fold objective and a resolution of 0.1 ⁇ m 2 per pixel; the bar represents a 100 ⁇ m segment.
  • FIG. 10 Lung function measurement 24 hours after the last allergen challenge.
  • EF 50 midexpiratory airflow
  • Mch methacholin
  • Animals have been sham-sensitized and -treated (NaCl/NaCl), OVA-sensitized and NaCl-treated (OVA/NaCl) or OVA-sensitized and treated with MALP-2+IFN- ⁇ (OVA/MALP-2+IFN- ⁇ ).
  • the vertical lines of each group give the Mch concentration that induces a 50% reduction of the EF 50 , i.e. the ED 50 .
  • Sensitization to OVA without treatment induces a significant (p ⁇ 0.05) reduction of the ED 50 compared to the unsensitized, sham-treated control and to the sensitized, MALP-2+IFN- ⁇ treated group.
  • An allergic reaction is characterized i.a. by an increased production of cytokines IL-4 and a decreased production of IFN ⁇ .
  • a useful model is to cocultivate allergen pulsed DC with autologous lymphocytes of patients suffering from an allergic disease.
  • monocytes were derived from the blood of volunteers who reacted positively to Dermatophagoides pteronyssinus allergen DerP1 in a prick test.
  • Four sets of DC cultures were set up. To one part of the DC only the allergen was added (group DerP1), another part was additionally treated with MALP-2 (group DerP1+MALP-2), another part with IFN ⁇ (group DerP1+IFN-g), and yet another part with both MALP-2 and IFN ⁇ (group DerP1+MALP-2+IFN-g). Further, there was an only solvent treated, unstimulated control (PBS). After cell harvest, all these groups were incubated with autologous lymphocytes (from the same volunteers).
  • Monocyte derived DC were generated as previously described (Weigt et al. Immunobiol. 207, 223-233 (2003). Briefly, blood was centrifuged to remove platelets, diluted and layered over Ficoll-Paque (Amersham Pharmacia, Uppsala, Sweden). After density gradient centrifugation, PBMC were collected, and monocytes were enriched using the MACS system and anti-CD 14 beads (Miltenyi Biotec, Bergisch Gladbach, Germany). The CD14 positive fraction (monocytes) was cultured in the serum-free medium X-VIVO 15 supplemented with 100 U/ml penicillin and 100 ng/ml streptomycin (all BioWhittaker, Verviers, Belgium).
  • the CD14 negative fraction containing the lymphocytes was cryopreserved in 90% FCS (GIBCO, Eggenstein-Leopoldhafen, Germany) and 10% DMSO (SIGMA, Taufkirchen, Germany).
  • FCS GEBCO, Eggenstein-Leopoldhafen, Germany
  • DMSO SIGMA, Taufmün, Germany
  • 800 U/ml of recombinant GM-CSF and 500 U/ml of recombinant IL-4 (Strathmann Biotec, Hamburg, Germany) were added to the monocyte culture to induce DC.
  • cells endocytose FITC-labeled Dextran and express the Toll-like receptors ⁇ 2 and ⁇ 6, which are associated with MALP-2 signaling.
  • DC were pulsed with affinity purified house dust mite allergen adjusted to a concentration of 100 ng/ml of DerP1 or with PBS as control.
  • DC were further treated with 100 pg/ml of MALP-2 synthesized and purified as described (Morr et al. Eur J Immunol 2002; 32(12):3337-47), 5000 U/ml of IFN-g (Strathmann Biotec), with both substances at the same concentrations or with PBS (control).
  • the respective optimal concentrations were experimentally determined using the highest expression of stimulatory cell surface molecules as read-out system. The substances were incubated on the cells for 48 hours.
  • Cytokine concentrations were determined in DC culture supernatant collected on day 7 (TNF- ⁇ , IL-10, IL-12) and in the supernatant of the coculture of DC and autologous lymphocytes collected on day 10 (IFN- ⁇ , IL-4).
  • Duo-Set ELISA kits for the detection of IL-12p70, IL-10, TNF, IFN- ⁇ , IL-4 and IL-5 were purchased (R&D Systems, Wiesbaden, Germany) and performed according to the manufacturers instructions.
  • DC was used for coculture experiments with autologous lymphocytes from day 7 to day 13.
  • DC were harvested and washed twice.
  • the cells were titrated in fresh medium in fresh round-bottom microtiterplates.
  • 1 ⁇ 10 5 vital cryopreserved autologous lymphocytes were added at ratios of DC to lymphocytes from 1:3 to 1:2187 in a final volume of 200 ⁇ l in serum-free XVIVO-15. No further stimulants were given.
  • the coculture was pulsed with 5 ⁇ Ci/ml 3 H-thymidine (Amersham Buchler, Braunschweig, Germany) on day 12. After 18 hours, the cells were harvested on filtermats (Canberra-Packard, Dreieich, Germany). After drying, 20 ⁇ l of liquid scintillator (Canberra-Packard) were added and the plates were sealed. Counts per minute were determined on a Topcount Microplate Scintillation Counter (Canberra-Packard).
  • IL-12p70 blocking antibody R&D Systems
  • DC pulsed with DerP1 induce a Th2-skewed immuneresponse in autologous lymphocytes of allergies
  • DC of house dust mite allergic donors and of healthy-control donors were pulsed with DerP1, the major allergen of the house dust mite Dermatophagoides pteronyssinus. Controls remained unpulsed. After a 2 day incubation period, DC were harvested and coincubated with autologous lymphocytes. Cell culture supernatant was collected on day 3 of the coculture and analyzed for the concentrations of IFN-g and IL-4 by ELISA ( FIG. 1 ). Using unpulsed DC, IFN-g concentrations of allergies and healthy donors were comparable (7.7 pg/ml ⁇ 3.7 (allergies) vs.
  • MALP-2 and IFN-g Synergistically Increase Surface Molecules Associated with Maturation of DC
  • TNF, IL-10 and IL-12p70 were analysed in the cell culture supernatants by ELISA after 7 days of cell culture. Stimulation with DerP1 or with IFN-g did not influence the production of IL-10 and IL-12 compared to untreated DC.
  • MALP-2 only induced IL-10 and had no effect on IL-12.
  • a striking difference was observed when stimulating with MALP-2 and IFN-g: IL-12 was massively increased, which was associated with the complete reduction of IL-10 to basal levels. ( FIG. 3 a,b ).
  • TNF was produced at low levels in the unstimulated control group and in the DerP1 pulsed group.
  • MALP-2 and IFN-g induced a comparable moderate release, while both stimuli together more than doubled the concentration of TNF compared to the single substances ( FIG. 3 c ).
  • DC were cocultured after their harvest on day 7 with autologous lymphocytes. Therefore, unbound stimulants were removed by washing, DC were seeded at various cell numbers in fresh medium and new cell culture plates, and a constant number of the cryopreserved autologous lymphocytes was added. To determine proliferation, the coculture was pulsed with 3 H-thymidine on day 12 for further 18 hours. In allergies, pulsing of DC with DerP1 airways resulted in a higher proliferative response in all preparations which was not observed in healthy control donors (data not shown). This demonstrates the induction of a secondary immuneresponse in the test system.
  • mice Female Balb/c mice (Charles River, Sulzfeld, Germany) were used at the age of 6-8 weeks in all experiments. They were fed with ovalbumin-free laboratory food and tap water ad libitum and held in a regular 12 h dark/light cycle at a temperature of 22° C. Before experimental start, mice were acclimated for a period of 7 days.
  • OVA-aerosols (grade V, Sigma) with a mean mass diameter of 1.49 ⁇ m were generated from a solution of 1 mg/ml OVA in 0.9% NaCl using a modified Pari Master system (Pari Maschinene, Sternberg, Germany) for 20 min.
  • a lung deposition of approximately 8 ⁇ g OVA per mice in each session was calculated by a respiratory minute volume of 35 ml/min an a deposition factor of 0.15 as brought forward by Raabe et al. (Raabe, O. G., J. E. Bennick, M. E. Light, C. H. Hobbs, R. L. Thomas, and M. I. Tillery. 1973 . Toxicol. Appl. Pharmacol. 26:264-273).
  • the study protocol is shown in FIG. 6 , and Tab. 3 gives the test groups.
  • mice were intratracheally treated with 20 ng macrophage activating lipopeptide-2 (MALP-2, synthesized and purified as described (Morr, M., O. Takeuchi, S. Akira, M. M. Simon, and P. F. Muhlradt. 2002 . Eur. J. Immunol. 32:3337-3347), 10 4 U IFN- ⁇ (Strathman Biotec, Hamburg, Germany), or a combination of both on day 27, 24 h before the allergen challenge (see FIG. 6 ). Controls were instillated with NaCl (see Tab. 3). Therefore, animals were anaesthetized by i.p.
  • MALP-2 macrophage activating lipopeptide-2
  • Mch methacholine
  • the aerosol concentration in the inhaled atmosphere was continuously determined during the provocation using a clean air mantle aerosol photometer.
  • the photometer was gravimetrically calibrated for aerosol.
  • the respiratory signals were calculated from a pneumotachograph (PTM 378/1.2, Hugo Sachs Electronics, March-Hugstetten, Germany) linked to a DP45-14 differential pressure transducer (Validyne, Northridge, USA) and amplified through a Carrier Frequency Bridge Amplifier; (Type 677, Hugo Sachs Electronics). Flow dependent respiratory signals were transduced into lung function parameters and continuously registered. For determination of bronchoconstriction, the midexpiratory airflow (EF50), i.e. the expiratory airflow (ml/s) at 50% tidal volume, was measured. Respiratory signals were analyzed using the Hem 3.4 system (Notocord systems S.A., Crossy-sur-Seine, F).
  • mice were killed with an i.p. injected overdose of pentobarbital-Na (Merial, Halbergmoos, Germany) after the lung function.
  • pentobarbital-Na (Merial, Halbergmoos, Germany) after the lung function.
  • mice were left untouched after the last allergen challenge and kept for another 7 days. Afterwards, they were dissected in the same way as the main groups as follows. Blood was obtained via punction of the vena cava. Red blood cells were lysed by incubation with 0.9% NH 4 Cl (Sigma) in H 2 O for 10 min, white blood cells were automatically counted using an AcT8 counter (Beckman Coulter, Krefeld, Germany) and cytospins were prepared for differential cell count.
  • the trachea was cannulated and broncho-alveolar lavage (BAL) was performed with 0.8 ml ice cold saline two times. BAL cells were separated by centrifugation, counted and cytospins were prepared as described above.
  • the BAL fluid (BALF) was aliquoted, shock frozen in liquid nitrogen and stored at ⁇ 80° C. until the determination of cytokines.
  • the lungs were filled with Tissue-Tek O.C.T. (Sakura Finetek, Zoeterwoude, Netherlands) diluted 1:2 in PBS and the trachea was ligated. Next, the right lungs were excised, subsequently shock frozen in liquid nitrogen and stored at ⁇ 80° C. for histology.
  • Cytospins were stained applying the Pappenheim method according to standard protocols. Leukocyte populations of blood and BAL were manually differentiated using a microscope and 630-fold magnification. 300 cells of each sample were determined, and absolute counts of macrophages, lymphocytes, eosinophilic and neutrophilic granulocytes were calculated.
  • cryostat sections were taken from frozen lungs and placed on slides. After acetone fixation (10 min. at ⁇ 20° C.) and washing in PBS, sections were stained with hematoxilin/eosin according to standard procedures and mounted in Entellan (Merck, Darmstadt, Germany). Photographies were taken using an Axioskop 2 microscope equipped with an Axiocam CCD camera and Axiovision acquisition software (all Carl Zeiss GmbH, Jena, Germany).
  • Duo-Set ELISA kits for the detection of IL-4, IL-5, IL-13 and IL-12p70 in the BAL supernatant were used (R&D Systems, Wiesbaden, Germany) according to the manufacturer's instructions.
  • the cytokines IL-4, IL-5, IL-13 and IL-12p70 were quantified in the BALF. Allergen sensitization resulted in the upregulation of the Th2 markers IL-4, IL-5 and IL-13 compared to the negative control, while the Th1 inducing IL-12p70 was not affected. This cytokine profile corresponds to a clear shift towards Th2 in the group injected and challenged with OVA. Local treatment with MALP-2 alone was able to reduce all Th2-markers to the level of the unsensitized negative control, but did not amplify IL-12p70.
  • MALP-2 and IFN- ⁇ Improve the Lung Function of Airflow Obstructed Animals
  • DC have the potential of inducing different responses in lymphocytes. Depending on DC treatment, lymphocytes get activated or anergic, polarized according to the Th1/2 model or become Th0. This potential is termed plasticity of DC (Huang et al. Science 2001; 294(5543):870-5). In this study, it was shown that only DerP1-pulsed, otherwise immature DC of house dust mite allergics induce an autologous Th2-response ( ⁇ IFN-g, ⁇ IL-4), but that equally treated DC of non-allergics have no effect on lymphocytes ( ⁇ IFN-g, ⁇ IL-4).
  • MALP-2 stimulation is known to induce maturation of DC. It upregulates costimulatory cell surface molecules and induces IL-10 secretion, while IL-12p70, a cytokine pivotal for inducing Th1 responses, was not produced.
  • MALP-2 treatment of DC leads to an enhanced lymphocyte proliferation, but does not influence the Th-polarization compared to unstimulated control-DC (Weigt et al. Immunobiol. 207, 1-11 (2003).
  • IFNg in contrast, is described to reduce immunostimulatory capacity of DC by downregulating costimulatory molecules (Rongcun et al. Cytokine 1998 October; 10(10):747-55).
  • Example 2 used a well established murine model of allergic airway inflammation and AHR, with OVA as allergen, to examine whether our earlier in vitro findings could be extended to an in vivo scenario.
  • NaCl/ OVA/ OVA/ OVA/ groups NaCl NaCl MALP-2 IFN- ⁇ MALP-2 + IFN- ⁇ sensitization/booster NaCl OVA OVA OVA OVA challenge OVA OVA OVA OVA OVA OVA OVA OVA OVA OVA treatment (i.t.) NaCl NaCl 20 ng MALP-2 10 4 U IFN- ⁇ 20 ng MALP-2 10 4 U IFN- ⁇ animal number (n) 8 16 8 8 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US10/559,375 2003-06-04 2004-06-03 Therapeutical Composition Containing Dentritic Cells And Use Thereof Abandoned US20070203185A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03012692A EP1484064A1 (de) 2003-06-04 2003-06-04 Therapeutische Zusammensetzung enthaltend dentritische Zellen und ihre Verwendung
EP03012692.4 2003-06-04
PCT/EP2004/005996 WO2004108145A1 (en) 2003-06-04 2004-06-03 Therapeutical composition containing dentritic cells and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/005996 A-371-Of-International WO2004108145A1 (en) 2003-06-04 2004-06-03 Therapeutical composition containing dentritic cells and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/875,393 Continuation US8415152B2 (en) 2003-06-04 2010-09-03 Therapeutical composition containing dentritic cells and use thereof

Publications (1)

Publication Number Publication Date
US20070203185A1 true US20070203185A1 (en) 2007-08-30

Family

ID=33155152

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/559,375 Abandoned US20070203185A1 (en) 2003-06-04 2004-06-03 Therapeutical Composition Containing Dentritic Cells And Use Thereof
US12/875,393 Expired - Fee Related US8415152B2 (en) 2003-06-04 2010-09-03 Therapeutical composition containing dentritic cells and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/875,393 Expired - Fee Related US8415152B2 (en) 2003-06-04 2010-09-03 Therapeutical composition containing dentritic cells and use thereof

Country Status (6)

Country Link
US (2) US20070203185A1 (de)
EP (2) EP1484064A1 (de)
AT (1) ATE460170T1 (de)
CA (1) CA2524910A1 (de)
DE (1) DE602004025936D1 (de)
WO (1) WO2004108145A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220265A1 (en) * 1996-12-17 2003-11-27 Muehlradt Peter F. Dihydroxypropyl cysteine peptide and agent containing this peptide
US11633458B2 (en) * 2013-11-08 2023-04-25 University Of Virginia Patent Foundation Compositions and methods for treating melanoma

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007122392A1 (en) * 2006-04-20 2007-11-01 King's College London Composition comprising a cytotoxic t-cell - inducing adjuvant
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
DE102011018499A1 (de) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
CN107921063A (zh) 2015-07-02 2018-04-17 普莱瓦克斯免疫肿瘤学公司 用于采用登革病毒与树突细胞的联合疗法的组合物及方法
EP3865150A1 (de) 2015-09-26 2021-08-18 Primevax Immuno-Oncology, Inc. Kombinationstherapie mit dem dengue-virus und dendritischen zellen
CA3082779A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
FR2796961B1 (fr) * 1999-07-29 2003-05-02 Chu Montpellier Procede d'obtention de cellules dentritiques, les cellules dentritiques ainsi obtenues et leurs utilisations a des fins cliniques
EP1291414A1 (de) * 2001-09-11 2003-03-12 Genethor GmbH Ex vivo Selektion von T-Zellen mit reduzierter Alloreaktivität (vermindertem Graft-versus-Host Effekt und erhöhtem Graft-verus-Leukemia Effekt) und Gebrauch derseleben bei Knochnemarktransplantationen
PL372098A1 (en) 2001-09-06 2005-07-11 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
EP1382352A1 (de) * 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220265A1 (en) * 1996-12-17 2003-11-27 Muehlradt Peter F. Dihydroxypropyl cysteine peptide and agent containing this peptide
US7435790B2 (en) * 1996-12-17 2008-10-14 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Dihydroxypropyl cysteine peptide and agent containing this peptide
US11633458B2 (en) * 2013-11-08 2023-04-25 University Of Virginia Patent Foundation Compositions and methods for treating melanoma

Also Published As

Publication number Publication date
EP1484064A1 (de) 2004-12-08
ATE460170T1 (de) 2010-03-15
DE602004025936D1 (de) 2010-04-22
EP1641474B1 (de) 2010-03-10
EP1641474A1 (de) 2006-04-05
WO2004108145A1 (en) 2004-12-16
CA2524910A1 (en) 2004-12-16
US20110070250A1 (en) 2011-03-24
US8415152B2 (en) 2013-04-09

Similar Documents

Publication Publication Date Title
US8415152B2 (en) Therapeutical composition containing dentritic cells and use thereof
EP1311658B1 (de) Verfahren zur herstellung gebrauchsfertiger, antigenbeladener oder -unbeladener, kryokonservierter, reifer dendritischer zellen
Sato et al. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse
Liau et al. Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens
US7553661B2 (en) Stromal antigen-presenting cells and use thereof
Giermasz et al. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines
CA2322712A1 (fr) Methodes d'activation de cellules tueuses naturelles (nk)
Itoh et al. Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells
CA2649290C (en) Allogeneic cell therapy for treatment of opportunistic infection
US20050042751A1 (en) Generation and use of new types of dendritic cells
US8282964B2 (en) Ex-vivo treatment of peripheral plasmacytoid dendritic cells with IFN-lambda
WO2012158556A1 (en) Tolerogenic plasmacytoid dendritic cells co-expressing cd8-alpha and cd8-beta and methods of inducing the differentiation of regulatory t cells using same
JP2004520033A (ja) 分化拘束された成熟樹状細胞の調製用補助組成物
AT412145B (de) Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
US20240076616A1 (en) Method for t-cell expansion and related medical applications
US20040241147A1 (en) New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions
DE60130206T2 (de) Zusammensetzungen und verfahren zur herstellung von antigen-präsentierenden zellen
ES2301494T3 (es) Celulas dendriticas activadas en presencia de hormonas glucocorticoides capaces de suprimir las respuestas de las celulas t especificas a un antigeno.
DK2847321T3 (en) PROCEDURE FOR IN-VITRO MATURING DENDRIT CELLS
EP1871872B1 (de) Verfahren zur aktivierung von cd8-t-zellen
Motiee et al. The Effect of Antigen Dose and Antigen Presenting Process on T Cell Stimulation: A Method for Enrichment of TB10. 4 Antigen-specific T-cell Clones
FR2775692A1 (fr) Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
CN117441678A (zh) 一种过继转移寻常型天疱疮动物模型的方法
US20040132185A1 (en) Cd8alphadendritic cell differentiated from human hematopoietic stem cell and a method for differentiation
US8771666B2 (en) Ex-vivo treatment of T-cells with IFN-λ

Legal Events

Date Code Title Description
AS Assignment

Owner name: HELMHOLTZ ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH, GE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUHLRADT, PETER F.;BRAUN, ARMIN;KRUG, NORBERT;AND OTHERS;REEL/FRAME:019155/0558;SIGNING DATES FROM 20070318 TO 20070323

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION